There are about 3133 clinical studies being (or have been) conducted in Romania. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
Evaluation of the clinical safety and effectiveness of an hydrophilic acrylic intraocular lens
Sore throat or acute tonsillopharyngitis, often referred to as angina catarrhalis in Central and Eastern Europe, affects mainly children, adolescents and young adults and represents one of the most common reasons to consult a family physician. While most patients complaining of sore throats have an infection, it has been estimated that fewer than 20% present with a clear indication for antibiotic therapy, i.e., are positive for hemolytic streptococcus. Acute tonsillopharyngitis (ATP) is a highly prevalent, seasonal infective disorder characterized by an inflammation of the pharynx and the palatine tonsils, which occurs in all age groups and accounts for about 5% of all visits in pediatric care. Common symptoms of ATP include sore throat, dysphagia, red pharynx, enlarged tonsils sometimes covered with exudate, fever with sudden onset, malaise, gastrointestinal complaints, halitosis, rhinorrhea and cough. Children with non-streptococcal tonsillopharyngitis are often over-treated with antibiotics. The scientific literature currently available shows that the extract of Pelargonium sidoides may be effective in the treatment of disorders affecting the respiratory tract. Evidence shows that zinc is beneficial for the common cold in healthy children and adults living in high-income countries and it may inhibit replication of the virus. In addition, zinc (lozenges or syrup) reduces the average duration of the common cold in healthy people assuming zinc within 24 hours of onset of symptoms Propolis has been widely investigated for its antibacterial, antiviral, and anti-inflammatory properties and is administered as an add-on therapy during watchful waiting for better control of symptoms in non-streptococcal pharyngitis. The above-mentioned considerations, have suggested Pediatrica Srl to develop a food supplement specific for pediatric age for the well-being of the airways (PediaFlù®). This product is actually on the market as adjuvant in seasonal diseases. The present clinical investigation is planned to verify and confirm these encouraging results in a setting of standard clinical practice. This is a randomized, open, controlled study to evaluate the efficacy and safety of PediaFlù® (dietary supplement) along with standard of care in children with acute tonsillopharyngitis / rhinopharyngitis versus standard of care only. The primary objective is to evaluate the efficacy and safety of the tested dietary supplement administered along with standard care vs standard care alone in children affected by acute tonsillopharyngitis (ATP). The secondary objectives of the study are the assessment of the use of rescue medicine (Ibuprofen or high dose of Paracetamol) and the evaluation of the overall improvement symptoms.
The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +/- X (where X is any additional drug). Adverse events and change in disease activity will be assessed. Venetoclax is an approved drug for the treatment of CLL. Study doctors put the participants in 1 of 2 groups, called cohorts, based on when symptoms of CLL came back after previous treatment in first-line. Approximately 75 adult participants with CLL who have been treated with venetoclax in combination with an anti-CD20 antibody +/- X will be enrolled in the study in approximately 60 sites worldwide. Participants will receive intravenous (IV) obinutuzumab + oral venetoclax (VenG) in 28-day cycles for a total of 6 cycles per cohort, followed by 6 to 18 cycles of venetoclax alone, for a total treatment of 12 to 24 cycles, depending on the cohort. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) or overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1 and ≥10.
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy/performance and safety of NBTXR3/RT±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with LA-HNSCC.
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting.
This is a double-blinded, two-arm, phase II study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis. The study includes a screening period, a treatment period and a follow-up period. At most, the study duration is 21 weeks.
The aim of this study is to test the feasibility and acceptability of a web-based adaptation of the Jobs program (developed by Curran et al., 1999).